Shu-Wei Chen1,2,3, Si-Hao Li2,3,4, Ding-Bo Shi2,3,5, Wen-Mei Jiang1,2,3, Ming Song1,2,3, An-Kui Yang1,2,3, Yu-Dong Li1,2,3, Jin-Xin Bei2,3,5, Wen-Kuan Chen1,2,3, Quan Zhang1,2,3. 1. Department of Head and Neck Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China. 2. State Key Laboratory of Oncology in South China, Guangzhou, China. 3. Collaborative Innovation Center of Cancer Medicine, Guangzhou, China. 4. Department of Surgical Oncology, Guangzhou Concord Cancer Center, Guangzhou, China. 5. Department of Experimental Research, Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China.
Abstract
OBJECTIVE: To investigate the role of programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and P16 in patients with head and neck squamous cell carcinoma (HNSCC). METHODS: A total of 95 paraffin-embedded samples of tumorous tissue of HNSCC were collected. Expression levels of PD-1, PD-L1, and P16 were determined by immunohistochemistry. RESULTS: A significantly higher proportion of PD-1 among patients infected with the human papillomavirus was found. PD-L1 expression is closely associated with the primary site of the tumor, postoperative recurrence, survival, PD-1 expression and P16 expression. Univariable analysis indicated that T stage, N stage, tumor node metastasis stage, tumor differentiation, and PD-L1 expression were all shown to be prognostic variables for overall survival in patients with HNSCC. In the multivariate analysis, only N stage (P = 0.010) and PD-L1 expression (P = 0.001) were found to be independent prognostic variables for overall survival. In addition, for disease recurrence, multivariate analysis showed that only PD-L1 expression was the associated independent risk factor. For the patients with negative PD-L1 expression, Kaplan-Meier analysis revealed that they had significantly worse outcomes in terms of overall survival (P = 0.001). Similarly, compared with the patients with positive PD-L1 expression, those with negative PD-L1 expression had a higher probability of recurrence (P = 0.026). CONCLUSIONS: The expression of PD-L1, PD-1, and P16 in HNSCC is significantly correlated. Human papillomavirus infection (P16 positive) is negatively related to postoperative recurrence. HNSCC patients with positive PD-L1/PD-1 expression tend to have better overall survival outcomes and lower probability of recurrence, providing more evidence for the PD-l-targeted immunotherapy of HNSCC.
OBJECTIVE: To investigate the role of programmed death-1 (PD-1), programmed death-ligand 1 (PD-L1), and P16 in patients with head and neck squamous cell carcinoma (HNSCC). METHODS: A total of 95 paraffin-embedded samples of tumorous tissue of HNSCC were collected. Expression levels of PD-1, PD-L1, and P16 were determined by immunohistochemistry. RESULTS: A significantly higher proportion of PD-1 among patients infected with the human papillomavirus was found. PD-L1 expression is closely associated with the primary site of the tumor, postoperative recurrence, survival, PD-1 expression and P16 expression. Univariable analysis indicated that T stage, N stage, tumor node metastasis stage, tumor differentiation, and PD-L1 expression were all shown to be prognostic variables for overall survival in patients with HNSCC. In the multivariate analysis, only N stage (P = 0.010) and PD-L1 expression (P = 0.001) were found to be independent prognostic variables for overall survival. In addition, for disease recurrence, multivariate analysis showed that only PD-L1 expression was the associated independent risk factor. For the patients with negative PD-L1 expression, Kaplan-Meier analysis revealed that they had significantly worse outcomes in terms of overall survival (P = 0.001). Similarly, compared with the patients with positive PD-L1 expression, those with negative PD-L1 expression had a higher probability of recurrence (P = 0.026). CONCLUSIONS: The expression of PD-L1, PD-1, and P16 in HNSCC is significantly correlated. Human papillomavirus infection (P16 positive) is negatively related to postoperative recurrence. HNSCC patients with positive PD-L1/PD-1 expression tend to have better overall survival outcomes and lower probability of recurrence, providing more evidence for the PD-l-targeted immunotherapy of HNSCC.
Entities:
Keywords:
Head and neck squamous cell carcinoma; P16; prognosis; programmed death-1; programmed death-ligand 1
Authors: Laura E Martínez; Shelly Lensing; Di Chang; Larry I Magpantay; Ronald Mitsuyasu; Richard F Ambinder; Joseph A Sparano; Otoniel Martínez-Maza; Marta Epeldegui Journal: Sci Rep Date: 2022-06-02 Impact factor: 4.996
Authors: M-N Theodoraki; S Laban; E K Jackson; R Lotfi; P J Schuler; C Brunner; T K Hoffmann; T L Whiteside; L Hofmann Journal: Br J Cancer Date: 2021-10-12 Impact factor: 7.640
Authors: Michael Berszin; Ioannis Michaelides; Julia Siemert; Louisa Röhl; Jana Wellhausen; Theresa Wald; Christopher Bohr; Julian Künzel; Tanja Gradistanac; Andreas Dietz; Veit Zebralla; Markus Pirlich; Susanne Wiegand; Gunnar Wichmann Journal: Front Oncol Date: 2022-02-28 Impact factor: 6.244